Werewolf Therapeutics Stock News

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have been given an average rating of Buy by the six ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12-month target price among analysts []

Acasti Pharma (NASDAQ:ACST) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends. Institutional and Insider Ownership 12.8% of Acasti Pharma shares are held by institutional investors. Comparatively, []

Zacks Investment Research lowered shares of Werewolf Therapeutics (NASDAQ:HOWL) from a hold rating to a sell rating in a research report sent to investors on Tuesday, Zacks.com reports. According to Zacks, Werewolf Therapeutics Inc. is a biopharmaceutical company. It involved in the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for []

Werewolf Therapeutics (NASDAQ:HOWL) had its target price lowered by equities researchers at SVB Leerink from $29.00 to $28.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has an outperform rating on the stock. SVB Leerinks price target would indicate a potential upside of 71.25% from the companys []

Geode Capital Management LLC acquired a new position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 108,178 shares of the companys stock, valued at approximately $1,886,000. A number of other institutional investors and hedge []

CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeuti

Posters Detail Preclinical Data on the Company's WTX-124 and WTX-330 Molecules for the Potential Treatment of Cancer Posters Detail Preclinical Data on the Company's WTX-124 and WTX-330 Molecules for

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeut

Werewolf Therapeutics to evaluate WTX-124, a systemically-delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE molecule, in combination with KEYTRUDA® (pembrolizumab) as a treatment for p

CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered t

- Recently completed upsized initial public offering raising $120.0 million in gross proceeds - - Recently completed upsized initial public offering raising $120.0 million in gross proceeds -

CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeuti

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeut